Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
G-CSF in Newly Diagnosed Severe Aplastic Anemia
NCT01163942Phase 3Terminated
- Start
- Mar 2001
- Primary completion
- Jun 2008
- Modality
- Cytokines & Interferons
- Countries
- 9
01
Overview
Phase 3, randomised, open-label trial of filgrastim in aplastic anemia (4 arms). Primary endpoint: Failure free survival at 240 days. Started Mar 2001; status: terminated.
02
Drugs
filgrastim
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on NCT01163942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01163942.